Cargando…

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial

Detalles Bibliográficos
Autores principales:	Fokkema, Cathelijne, Moreau, Phillipe, van der Holt, Bronno, Lambert, Jérôme, van Duin, Mark, Wester, Ruth, Jongen, Joost L.M., van Doorn, Pieter A., Godet, Sophie, Jie, KonSiong, Fitoussi, Olivier, Delforge, Michel, Keita-Manta, Awa, Luycx, Odile, Cupedo, Tom, van de Donk, Niels W.C.J., Zweegman, Sonja, Vermeulen, Jessica T., Sonneveld, Pieter, Broijl, Annemiek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244836/ https://www.ncbi.nlm.nih.gov/pubmed/35295081 http://dx.doi.org/10.3324/haematol.2021.280567

Ejemplares similares

OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy
por: Tahri, Sabrin, et al.
Publicado: (2022)

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
por: Hofste op Bruinink, Davine, et al.
Publicado: (2022)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021)

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
por: Hulin, Cyrille, et al.
Publicado: (2021)

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018
por: Brink, Mirian, et al.
Publicado: (2021)

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
por: Wester, Ruth, et al.
Publicado: (2020)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
por: Wester, Ruth, et al.
Publicado: (2022)

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
por: Wester, Ruth, et al.
Publicado: (2019)

B01: STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT IN MULTIPLE MYELOMA
por: de Jong, M, et al.
Publicado: (2022)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
por: Wester, R., et al.
Publicado: (2023)

VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma
por: Broijl, Annemiek, et al.
Publicado: (2021)

Inference of single-cell phylogenies from lineage tracing data using Cassiopeia
por: Jones, Matthew G, et al.
Publicado: (2020)

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2022)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020)

B05 PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM
por: Hofste op Bruinink, D., et al.
Publicado: (2023)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Brink, Mirian, et al.
Publicado: (2021)

Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
por: Ubels, Joske, et al.
Publicado: (2018)

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
por: Brink, Mirian, et al.
Publicado: (2022)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

A new species of rake-legged mite, Caeculus cassiopeiae (Prostigmata, Caeculidae), from Canada and a systematic analysis of its genus
por: Bernard, Jared, et al.
Publicado: (2020)

A unique presentation of pulmonary disease in advanced systemic mastocytosis, proven by the presence of mast cells in bronchoalveolar lavage: a case report
por: Hermans, Maud A. W., et al.
Publicado: (2016)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS
por: Bruins, Wassilis, et al.
Publicado: (2023)

Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study
por: Bennink, Christine, et al.
Publicado: (2023)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023)

Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma
por: Amin, Samirkumar B., et al.
Publicado: (2014)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
por: Musto, Pellegrino, et al.
Publicado: (2021)

Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice
por: Oerlemans, Simone, et al.
Publicado: (2020)

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
por: Zweegman, Sonja, et al.
Publicado: (2020)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
por: Ramasamy, Karthik, et al.
Publicado: (2023)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
por: Caers, Jo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9857efr0chhas1et0g60kusd2v